NovaBridge Biosciences (NBP) awards 949,050 long-dated stock options to its CCO

Rhea-AI Filing Summary

NovaBridge Biosciences reported that Chief Commercial Officer Mark Arnold Hagler received a grant of 949,050 2025 Employee Share Options, each representing a right to buy American Depositary Shares (ADS) at an exercise price of $1.93 per ADS. These options have an expiration date of July 8, 2036 and, according to the vesting terms, become exercisable in four equal annual installments beginning on the first anniversary of April 17, 2026. The options relate to Ordinary Shares that may be represented by ADSs, where each 10 ADSs represent 23 Ordinary Shares. Following this award, Hagler holds 949,050 derivative securities of this type directly.

Insights

Equity Compensation Analyst

Large stock option grant to CCO, standard vesting and long-dated expiry; routine equity compensation event.

The Chief Commercial Officer of NovaBridge Biosciences received a grant of 949,050 employee share options with an exercise price of $1.93 per ADS. This is classified as a grant/award acquisition, not an open-market purchase, so it represents equity-based compensation rather than discretionary buying.

The options vest in four equal annual installments starting on the first anniversary of April 17, 2026, creating a multi-year retention and performance incentive. The options expire on July 8, 2036, giving a long window during which value may be realized if the share price exceeds the $1.93 exercise price. The filing also notes that each 10 ADSs represent 23 Ordinary Shares, clarifying how the derivative relates to the company’s underlying equity structure.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hagler Mark Arnold

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	2025 Employee Share Option (right to buy)	949,050	$0.00	--

Holdings After Transaction: 2025 Employee Share Option (right to buy) — 949,050 shares (Direct, null)

Footnotes (1)

1. Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of April 17, 2026. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

Key Figures

Options Granted: 949,050 options Exercise Price: $1.93 per ADS Expiration Date: July 8, 2036 +3 more

6 metrics

Options Granted 949,050 options 2025 Employee Share Option grant to Chief Commercial Officer

Exercise Price $1.93 per ADS Exercise price for the 2025 Employee Share Options

Expiration Date July 8, 2036 Option expiration date for the granted 2025 Employee Share Options

Vesting Commencement Reference First anniversary of April 17, 2026 Vesting begins on the first anniversary of April 17, 2026, in four equal annual installments

ADS to Ordinary Share Ratio 10 ADSs represent 23 Ordinary Shares Relationship between ADSs and Ordinary Shares for this option grant

Post-Transaction Derivative Holdings 949,050 derivative securities Total options of this type held directly after the grant

Key Terms

American Depositary Shares ("ADS"), exercise price, vests and becomes exercisable, Ordinary Shares

4 terms

American Depositary Shares ("ADS") financial

"Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS")."

American depositary shares are U.S.-listed certificates issued by a bank that represent ownership in shares of a foreign company, trading on American exchanges in dollars. Think of them as voucher tickets that let U.S. investors buy and sell foreign stock without handling foreign exchanges, currencies, or settlement rules directly. They matter because they make cross-border investing simpler and can affect liquidity, dividend payments and currency exposure for investors.

exercise price financial

"Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS")."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable in four equal annual installments"

Ordinary Shares financial

"The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 05:00 PM Accepted by SEC EDGAR 07/10/2026 - 05:00 PM Learn about SEC filing dates

FAQ

What equity award did NovaBridge Biosciences (NBP) grant to its Chief Commercial Officer?

NovaBridge Biosciences granted its Chief Commercial Officer 949,050 2025 Employee Share Options. These options are exercisable for ADSs at an exercise price of $1.93 per ADS and function as equity-based compensation, not an open-market purchase.

What is the exercise price and expiry of the options reported for NBP’s Chief Commercial Officer?

The options have an exercise price of $1.93 per ADS and expire on July 8, 2036. This long-dated expiration provides a substantial time window for potential value realization if the share price exceeds the exercise price.

How do the NovaBridge Biosciences (NBP) options for the CCO vest over time?

The option grant to the CCO vests and becomes exercisable in four equal annual installments beginning on the first anniversary of April 17, 2026. This multi-year vesting schedule aligns the executive’s incentives with longer-term company performance.

How many derivative securities does NBP’s Chief Commercial Officer hold after this Form 4 transaction?

After the reported transaction, the Chief Commercial Officer holds 949,050 derivative securities of this option type directly. This reflects the full amount of the new grant, classified as a grant or award acquisition rather than a market trade.

What is the relationship between NovaBridge Biosciences ADSs and Ordinary Shares in this Form 4?

The filing states that the Ordinary Shares may be represented by ADSs and that each 10 ADSs represent 23 Ordinary Shares. The number of underlying securities and the exercise price for this option grant are expressed in terms of ADSs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hagler Mark Arnold

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2025 Employee Share Option (right to buy)	$1.93(1)	07/08/2026		A		949,050(1)		(2)	07/08/2036	Ordinary Shares(3)	949,050(1)	$0	949,050(1)	D

Explanation of Responses:

1. Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS").

2. The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of April 17, 2026.

3. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

	/s/ Kyler Lei as attorney-in-fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)